Search - tctmd.com

Displaying 221 - 240 of 367

Sort: Relevancy | Date

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

Presentation TVT 2022

TAVR Unload

Presenter: Nicolas Van Mieghem

June 10, 2022

RELIEVE HF: Different Patient Selection and Study Design – Should We Expect Different Results?

Presentation TVT 2022

Less Invasive Ventricular Enhancement for HFrEF

Presenter: John Boehmer

June 10, 2022

Presentation TVT 2022

Post-TAVR Heart Failure: Mechanism, Incidence, Risk Factors, and Treatment

Presenter: Chetan Huded

June 10, 2022

Presentation TVT 2022

The Accucinch Ventricular Restoration System for HFrEF

Presenter: Ulrich Jorde

June 10, 2022

Presentation TVT 2022

Rationale for Physical Reverse LV Remodeling as a Therapy for HFrEF

Presenter: Daniel Burkhoff

June 10, 2022

Presentation TVT 2022

Design and Rationale of the CORCINCH-HF Pivotal Study

Presenter: Ulrich Jorde

June 09, 2022

Presentation TVT 2022

12-Month Outcomes for the AccuCinch System in HFrEF

Presenter: Nadira Hamid

June 09, 2022

Presentation TVT 2022

From Access to Anchors: The AccuCinch Ventricular Restoration System

Presenter: Azeem Latib

June 09, 2022

Presentation TVT 2022

Reverse Remodeling in Heart Failure

Presenter: Daniel Burkhoff

June 09, 2022

News Daily News

Heart Failure Risks of Smoking Can Linger for Decades

L.A. McKeown

June 07, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

Podcast TCTMD Talking Points

The LIFE Trial

May 18, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

Advertisement

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

TAVR Unload

Less Invasive Ventricular Enhancement for HFrEF

Post-TAVR Heart Failure: Mechanism, Incidence, Risk Factors, and Treatment

The Accucinch Ventricular Restoration System for HFrEF

Rationale for Physical Reverse LV Remodeling as a Therapy for HFrEF

Design and Rationale of the CORCINCH-HF Pivotal Study

12-Month Outcomes for the AccuCinch System in HFrEF

From Access to Anchors: The AccuCinch Ventricular Restoration System

Reverse Remodeling in Heart Failure

Heart Failure Risks of Smoking Can Linger for Decades

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

The LIFE Trial

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

TCTMD’s Top 10 Most Popular Stories for April 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content